Eloxx Pharmaceuticals (ELOX) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $59.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | KLRS |
|---|---|---|
| Share price | $15.18 | $2.50 |
| Market cap | $61.27M | $59.51M |
| 1-day change | +2.02% | -2.34% |
| YTD return | — | -70.38% |
| 1-year return | — | -62.06% |
| 5-year return | — | -99.51% |
| P/E ratio (TTM) | 4.31 | — |
| EPS (TTM) | $3.52 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $11.88 |
| 52-week low | $8.20 | $2.35 |
| Distance from 52-week high | -35.13% | -78.96% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +151.98% | +648.40% |
| Average volume | 44.52K | 252.88K |
| Shares outstanding | 4.04M | 23.80M |
| Employees | 10 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
ELOX vs KLRS FAQ
Which is bigger, Eloxx Pharmaceuticals or Kalaris Therapeutics?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $59.51M for Kalaris Therapeutics (KLRS).
Are Eloxx Pharmaceuticals and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.